Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells

Cancer Research

Volumn 58, Issue 19, 1998, Pages 4453-4460

  Fulda, Simone ^a   Susin, Santos A ^b   Kroemer, Guido ^b   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETULIC ACID; DEOXYCORTICOSTERONE ACETATE; DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; NEUROBLASTOMA; PRIORITY JOURNAL;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CYTOSOL; DNA, NEOPLASM; DOXORUBICIN; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR MEMBRANES; MEMBRANE GLYCOPROTEINS; MEMBRANE POTENTIALS; MITOCHONDRIA; MODELS, BIOLOGICAL; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; TRITERPENES; TUMOR CELLS, CULTURED;

EID: 0032189535     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
2. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B. C., Ponstingl, H., and Krammer, P. H. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J. Biol. Chem., 267: 10709-10715, 1992.
3. Trauth, B. C., Klas, C., Peter, A. M. J., Matz, S., Möller, P., Falk, W., Debatin, K-M., and Krammer, P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301-305, 1989.
4. Debatin, K-M. Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohaematopoietic cells. Cell Death Differ., 3: 185-189, 1996.
5. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
6. Peter, M. E., Kischkel, F. C., Hellbrandt, S., Chinnaiyan, A. M., Krammer, P. H., and Dixit, V. M. CD95 (APO-1/Fas)-associating signaling proteins. Cell Death Differ., 3: 161-170, 1996.
7. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A. N. J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85: 817-827, 1996.
8. Chinnaiyan, A. M., Teppert, C. G., Seidin, M. F., O'Rourke, K., Kischkel, F. C., Hellbrandt, S., Peter, M. E., and Dixit, V. M. FADD/MORT-1 is a common mediator of CD95 (APO-1/Fas) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem., 271: 4961-4965, 1996.
9. Kischkel, F. C., Hellbrandt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins (CAP) form a death-inducing signaling complex (DISC) with the receptor. EMBO J., 14: 5579-5588, 1995.
10. Medema, J. P., Scaffidi, C., Kischkel, F. C, Shevchenko, A. N. J., Mann, M., Krammer, P. H., and Peter, M. E. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J., 16: 2794-2804, 1997.
11. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., Liwack, G., and Alnemri, E. S. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. USA, 93: 14486-14491, 1996.
12. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
13. Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K-M. The CD95 (APO-1/ Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res., 57: 3823-3829, 1997.
14. Fulda, S., Los, M., Friesen, C., and Debatin, K-M. Chemosensitivity of solid tumor cells is associated with activation of the CD95 system. Int. J. Cancer, 76: 105-114, 1998.
15. Los, M., Herr, I., Friesen, C., Fulda, S., Schulze-Osthoff, K., and Debatin, K-M. Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood, 90: 3118-3129, 1997.
16. Friesen, C., Fulda, S., and Debatin, K-M. Deficient activation of the CD95 (APO-1/ Fas) system in drug-resistant cells. Leukemia (Baltimore), 11: 1833-1841, 1997.
17. Debatin, K-M. Anticancer drugs, programmed cell death and the immune system: defining new roles in an old play. J. Natl. Cancer lnst. (Bethesda), 89: 750-751, 1997.
18. Müller, M., Strand, S., Hug, H., Heinemann, E-M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest., 99: 403-413, 1997.
19. Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nuñez, G., Krammer, P. H., Peter, M. E., and Debatin, K-M. Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res., 57: 4956-4964, 1997.
20. Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tun, J. S., Earnshaw, W. C., Leibson, P. J., and Kaufmann, S. H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90: 935-943, 1997.
21. Villunger, A., Egle, A., Kos, M., Hartmann, B., Geley, S., Kofler, R., and Greil, R. Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res., 57: 3331-3334, 1997.
22. Kroemer, G., Zamzami, N., and Susin, S. A. Mitochondrial control of apoptosis. Immunol. Today, 18: 44-51, 1997.
23. Susin, S. A., Zamzami, N., Castedo, M., Daugas, E., Wang, H. G., Geley, S., Fassy, F., Reed, J. C., and Kroemer, G. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95-and ceramide-induced apoptosis. J. Exp. Med., 186: 25-37, 1997.
24. Marchetti, P., Castedo, M., Susin, S. A., Zamzami, N., Hirsch, T., Macho, A., Haeffner, A., Hirsch, T., Geuskens, M., and Kroemer, G. Mitochondrial permeability transition is a central coordinating event of apoptosis. J. Exp. Med., 184: 1155-1160, 1996.
25. Zamzami, N., Susin, S. A., Marchetti, P., Hirsch, T., Gomez-Monterrey, I., Castedo, M., and Kroemer, G. Mitochondrial control of nuclear apoptosis. J. Exp. Med., 183: 1533-1544, 1996.
26. Susin, S. A., Zamzami, N., Castedo, M., Hirsch, T., Marchetti, P., Macho, A., Daugas, E., Geuskens, M., and Kroemer, G. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med., 184: 1331-1341, 1996.
27. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res., 57: 62-67, 1997.
28. Susin, S. A., Zamzami, N., Larochette, N., Dallaporta, B., Marzo, L. Brenner, C., Hirsch, T., Petit, P. X., Geuskens, M., and Kroemer, G. A cytofluorometric assay of nuclear apoptosis. Application to ceramide-induced apoptosis. Exp. Cell Res., 236: 397-403, 1997.
29. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Washington DC), 275: 1132-1136, 1997.
30. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T. I., Jones, D. P., and Wang, X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (Washington DC), 275: 1129-1132, 1997.
31. Liu, X., Kim, C. N., Yang, J., Jemmerson, R., and Wang, X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 86: 147-157, 1996.
32. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S., Ahmad, M., Alnemri, A. S., and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997.
33. Kantrow, S. P., and Piantadosi, C. A. Release of cytochrome c from liver mitochondria during permeability transition. Biochem. Biophys. Res. Commun., 232: 669-671, 1997.
34. Ellerby, H. M., Martin, S. J., Ellerby, L. M., Naiem, S. S., Rabizadeh, S., Salvesen, G. S., Casiano, C. A., Cashman, N. R., Green, D. R., and Bredesen, D. E. Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases. J. Neurosci., 17: 6165-6178, 1997.
35. Marzo, I., Brenner, C., Zamzami, N., Susin, S. A., Beutner, G., Brdiczka, D., Remy, R., Xie, Z-H., Reed, J. C., and Kroemer, G. The permeability transition pore complex: a target for apoptosis regulation by caspases and Bcl-2 related proteins. J. Exp. Med., in press, 1998.
36. Kroemer, G. The protooncogene Bcl-2 and its role in regulating apoptosis. Nat. Med., 3: 614-620, 1997.
37. Reed, J. C. Double identity for proteins of the Bcl-2 family. Nature (Lond.), 387: 773-776, 1997.
38. L inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res., 57: 3115-3120, 1997.
39. Dole, M., Nuñez, G., Merchant, A. K., Maybaum, J., Rode, C. K., Bloch, C. A., and Castle, V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res., 54: 3253-3259, 1994.
40. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55: 2576-2582, 1995.
41. L inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res., 56: 4743-4748, 1996.
42. L regulates the membrane potential and volume homeostasis of mitochondria. Cell, 91: 627-637, 1997.
43. Bossy-Wetzel, E., Newmeyer, D. D., and Green, D. R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J., 17: 37-49, 1998.
44. Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. Apaf-1, a human protein homologous to C.elegans CED-4, participates in cytochrome r-dependent activation of caspase-3. Cell, 90: 405-413, 1997.
45. Hengartner, M. O. Ced-4 is a stranger no more. Nature (Lond.), 388: 734-735, 1997.
46. L and Apaf-1 form a ternary complex. J. Biol. Chem., 273: 5841-5845, 1998.
47. L interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. USA, 95: 4386-4391, 1998.
48. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
49. Scaffidi, C, Medema, J. P., Krammer, P. H., and Peter, M. E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem., 272: 26953-26958, 1997.
50. Scaffidi, C., Fulda, S., Li, F., Friesen, C., Srinivasan, A., Tomaselli, K. J., Debatin, K-M., Krammer, P. H., and Peter, M. E. Two CD95 signaling pathways. EMBO J., 17: 1675-1687, 1998.
51. L acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex. J. Biol. Chem., 273: 3388-3393, 1998.
52. L functions downstream of caspase-8 to inhibit Fas-and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells. J. Biol. Chem., 273: 4523-4529, 1998.
53. L can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc. Natl. Acad. Sci. USA. 94: 3759-3764, 1997.
54. Hirata, H., Takahashi, A., Kobayashi, S., Yonehara, S., Sawai, H., Okazaki, T., Yamamoto, K., and Sasada, M. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med., 187: 587-600, 1998.
55. Liu, X., Zou, H., Slaughter, C., and Wang, X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell, 89: 175-184, 1997.
56. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature (Lond.), 391: 43-50, 1997.
57. Herr, I., Boehler, T., Wilhelm, D., Angel, P., and Debatin, K-M. Activation of the CD95 (APO-1/Fas) pathway by ceramide mediates radio-and chemotherapy-induced apoptosis. EMBO J., 16: 6200-6208, 1997.
58. Faris, M., Kokot, N., Latinis, K., Kasibhatla, S., Green, D. R., Koretzky, G. A., and Nel, A. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J. Immunol., 160: 134-144, 1998.
59. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E., and Radinsky, R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol.l 15: 3032-3040, 1995.
60. De Maria, R., Lenti, L., Malisand, F., Agostino, F., Tomassini, B., Zeuner, A., Rippo, M. R., and Testi, R. Requirement for GD3 ganglioside in CD95-and ceramide-induced apoptosis. Science (Washington DC), 277: 1652-1655, 1997.